Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • Catharina Schuetz - , Ulm University (Author)
  • Manfred Hoenig - , Ulm University (Author)
  • Despina Moshous - , Université Paris Cité, Necker–Enfants Malades Hospital, Imagine Institute (Author)
  • Christof Weinstock - , Ulm University (Author)
  • Martin Castelle - , Université Paris Cité (Author)
  • Matthieu Bendavid - , Université Paris Cité (Author)
  • Kristin Shimano - , University of California at San Francisco (Author)
  • Vanessa Tolbert - , University of California at San Francisco (Author)
  • Ansgar S. Schulz - , Ulm University (Author)
  • Christopher C. Dvorak - , University of California at San Francisco (Author)

Abstract

New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post-hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune dysregulation including autoimmune cytopenias. We describe an innovative therapy for AIHA refractory to proteasome inhibition. In potentially life-threatening AIHA in the context of HSCT, daratumumab may be an effective rescue therapy.

Details

Original languageEnglish
Pages (from-to)2550-2553
Number of pages4
JournalBlood advances
Volume2
Issue number19
Publication statusPublished - 9 Oct 2018
Peer-reviewedYes
Externally publishedYes

External IDs

PubMed 30291113
ORCID /0009-0003-6519-0482/work/149439126

Keywords

ASJC Scopus subject areas